# EDGAR Filing Document

**Accession Number:** 0001801198
**File Stem:** 0001193125-23-039019
**Filing Date:** 2023-2
**Character Count:** 8200
**Document Hash:** 38d39c27f89bded0d06048f3d0b3525d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-039019.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001193125-23-039019

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Legend Biotech Corp
- **CENTRAL INDEX KEY:** 0001801198
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92217
- **FILM NUMBER:** 23628594

**BUSINESS ADDRESS:**
- **STREET 1:** 2101 COTTONTAIL LANE
- **CITY:** SOMERSET
- **STATE:** NJ
- **ZIP:** 08873
- **BUSINESS PHONE:** 732-317-5050

**MAIL ADDRESS:**
- **STREET 1:** 2101 COTTONTAIL LANE
- **CITY:** SOMERSET
- **STATE:** NJ
- **ZIP:** 08873
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GenScript Biotech Corp
- **CENTRAL INDEX KEY:** 0001845272
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** NO. 28 YONGXI ROAD, JIANGNING DISTRICT
- **STREET 2:** JIANGSU
- **CITY:** NANJING
- **STATE:** F4
- **ZIP:** 211100
- **BUSINESS PHONE:** 8602558897288

**MAIL ADDRESS:**
- **STREET 1:** NO. 28 YONGXI ROAD, JIANGNING DISTRICT
- **STREET 2:** JIANGSU
- **CITY:** NANJING
- **STATE:** F4
- **ZIP:** 211100

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

------

**SCHEDULE 13G** 

**Under the Securities Exchange Act of 1934** 

**(Amendment No. 2)\*** 

------

## Legend Biotech Corporation
**(Name of Issuer)** 

**Ordinary Shares** 

**(Title of Class of Securities)** 

**52490G102** 

**(CUSIP Number)** 

**December 31, 2022** 

**(Date of Event Which Requires Filing of This Statement)** 

------

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

CUSIP No. 52490G102 13G/A Page 2 of 4

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;NAMES OF REPORTING PERSONS<br>&nbsp;&nbsp;&nbsp;&nbsp;GenScript Biotech Corporation |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;Cayman Islands |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;174,497,556 (1) |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;174,497,556 (1) |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;174,497,556 (1) |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;52.12% (2) |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;TYPE OF REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;CO, FI |

---

(1) Represents the sum of (i) 169,680,000 ordinary shares held by GenScript Biotech Corporation
("GenScript") before the Issuer's initial public offering completed in June 2020 (the "IPO"), (ii) 1,043,478 ordinary shares issued to GenScript in a private placement transaction that closed concurrently with the IPO, which
was reduced by 725,922 ordinary shares that were distributed by GenScript to its shareholders in connection with the IPO to effect an assured entitlement distribution pursuant to the rules of the Hong Kong Stock Exchange and (iii) 2,250,000 American
Depositary Shares that were purchased in connection with the Issuer's follow-on offering completed in December 2021.

(2) This percentage is calculated based on 334,805,584 ordinary shares issued and outstanding as of
September 13, 2022, as reported in the Issuer's Proxy Statement furnished to the Securities and Exchange Commission under the cover of a Form 6-K on September 16, 2022.

------

CUSIP No. 52490G102 13G/A Page 3 of 4

**Item 1(a). Name of Issuer:** 

Legend Biotech Corporation (the "Issuer")

**Item 1(b). Address of Issuer's Principal Executive Officers:** 

The Issuer's principal executive office is located at 2101 Cottontail Lane, Somerset, New Jersey 08873.

**Item 2(a). Name of Person Filing:** 

GenScript Biotech Corporation

**Item 2(b). Address or Principal Business Office or, if None, Residence:** 

The headquarter and principal business office for the Reporting Person in the People's Republic of China is No. 28, Yongxi Road, Jiangning Science Park, Nanjing, Jiangsu Province, China 211100.

**Item 2(c). Citizenship:** 

See Item 4 of the cover page.

**Item 2(d). Title of Class of Securities:** 

American Depositary Shares, each representing two ordinary shares, par value US$0.0001 per share.

**Item 2(e). CUSIP No.:** 

52490G102

**Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c)** 

Not applicable.

**Item 4. Ownership.** 

The percentage set forth in this Schedule 13G/A is calculated based upon an aggregate of 334,805,584 Ordinary Shares outstanding as of September 13, 2022, as reported in the Issuer's Proxy Statement furnished to the Securities and Exchange Commission under the cover of a Form 6-K on September 16, 2022**.**

The information required by Items 4(a)—(c) is set forth in Rows 5—11 of the cover page for the Reporting Person and is incorporated herein by reference.

**Item 5. Ownership of 5 Percent or Less of a Class.** 

Not applicable.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.** 

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.** 

Not applicable.

**Item 8. Identification and Classification of Members of the Group.** 

Not applicable.

**Item 9. Notice of Dissolution of Group.** 

Not applicable.

**Item 10.** **Certifications.** <br>

Not applicable.

------

CUSIP No. 52490G102 13G/A Page 4 of 4

**SIGNATURE** 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| Date: February 13, 2023 | **GenScript Biotech Corporation** | **GenScript Biotech Corporation** |
|  | By: | /s/ Jiange Meng |
|  | Name: Jiange Meng | Name: Jiange Meng |
|  | Title: Chairman | Title: Chairman |

---